As interest in CAR T cells and immune-based oncology therapies increases, efficient phenotyping of cell therapy products ...

CAR T cell therapy has revolutionized the treatment of many blood cancers, but has shown little success against solid tumors, which account for over 85% of all cancers.

The potential transaction is being explored to augment Tevogen’s existing capabilities and would result in Tevogen becoming a revenue-generating healthcare enterprise. Tevogen is evaluating the ...

And that was also presented at ASH 2025 and also a very, very strong data set. I should mention that BI-1808 that was monotherapy, single-agent therapy. Then, we also started our Phase IIa trial ...

A new, highly sensitive cell therapy was able to wipe out three different kinds of solid tumors in mice, an important advance in an area where CAR-T cells have long struggled. But significant ...

Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as ...

Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing processReceived FDA ...

So far, in a Phase I trial, incidents of CRS have been low grade on VIR-5500, and 14 of 17 evaluable patients saw more than a 50 percent decrease in PSA levels.

In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

Scorpius Holdings Inc. research and ratings by Barron's. View SCPX revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients ...